← Back to Search

Radiation

Accelerated Radiation Therapy for Lung Cancer

Phase 1

Recruiting

Led By Lucas K Vitzthum, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy

ECOG performance status of 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months

Awards & highlights

Study Summary

This trial looks at using a shorter form of radiation therapy to treat lung cancer. Depends on size/location of the tumor.

Who is the study for?

This trial is for adults over 18 with lung cancer who are fit enough to give consent and undergo treatment. They should expect to live at least 12 weeks, have a certain level of physical fitness (ECOG 0-2), and be ready for radiation therapy alongside other treatments.Check my eligibility

What is being tested?

The study tests hypofractionated accelerated radiation therapy (HART) on patients with advanced lung cancer. It aims to see how well this intense, targeted radiation works when the tumor's size and location vary.See study design

What are the potential side effects?

While not specified here, HART may cause skin irritation, fatigue, shortness of breath, coughing or chest pain due to its intensity compared to standard radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is confirmed by tests and I am set for specific radiation and concurrent therapy.

Select...

I am able to care for myself and perform daily activities.

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting pulmonary and esophageal toxicity

Secondary outcome measures

Acute and Late Toxicities

Integrated adaptive dosing regimen with an automated planning system

Local control

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Hypofractionated accelerated radiation therapy (HART)Experimental Treatment1 Intervention

Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,305 Total Patients Enrolled

LUNGevity FoundationOTHER

7 Previous Clinical Trials

1,601 Total Patients Enrolled

Lucas K Vitzthum, MDPrincipal InvestigatorStanford University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA officially sanctioned Arm 1- Hypofractionated accelerated radiation therapy (HART)?

"We believe that the safety of Arm 1- Hypofractionated accelerated radiation therapy (HART) is a 1 on a scale from 1 to 3 because there are limited studies concerning its efficacy and evidence for safety."

Answered by AI

Are there openings in this experiment for participants?

"The clinicaltrials.gov website suggests that this particular research is not actively seeking participants, having last been updated on October 6th 2023 since its inception on the 31st of October. Nevertheless, 1640 different trials are currently open to enrolment at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

2023. "Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06080061.